Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable?
Authors:
- 20 February 2021
- journal article
- letter
- Published by Elsevier in Medical Hypotheses
- Vol. 149, 110539
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2Journal of Molecular Graphics and Modelling, 2020
- Life-threatening course in coronavirus disease 2019 (COVID-19): Is there a link to methylenetetrahydrofolic acid reductase (MTHFR) polymorphism and hyperhomocysteinemia?Medical Hypotheses, 2020
- High dose folic acid is a potential treatment for pulmonary hypertension, including when associated with COVID-19 pneumoniaMedical Hypotheses, 2020
- A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19New England Journal of Medicine, 2020
- The first experience with Angiovit in the combination treatment of acute COVID-19 infectionNeurology, Neuropsychiatry, Psychosomatics, 2020
- SARS CoV‐2 aggravates cellular metabolism mediated complications inCOVID‐19 infectionDermatologic Therapy, 2020
- In silico virtual screening-based study of nutraceuticals predicts the therapeutic potentials of folic acid and its derivatives against COVID-19Research Square, 2020
- Clinical Characterization of 162 COVID-19 patients in Israel: Preliminary Report from a Large Tertiary Center.2020
- Predictors for imaging progression on chest CT from coronavirus disease 2019 (COVID-19) patientsAging, 2020
- The Role of Folic Acid in the Management of Respiratory Disease Caused by COVID-19ChemRxiv, 2020